Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
RECTIV vs IMDUR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
RECTIV (nitroglycerin) is a nitric oxide (NO) donor that relaxes vascular smooth muscle via stimulation of intracellular cyclic guanosine monophosphate (c GMP) production, leading to vasodilation. In chronic anal fissures, it reduces internal anal sphincter pressure and improves blood flow to the anoderm.
Isosorbide mononitrate is a nitrate vasodilator that relaxes vascular smooth muscle via conversion to nitric oxide (NO), which activates guanylate cyclase, increasing c GMP levels, leading to vasodilation. It primarily dilates veins (venodilation) with lesser effects on arteries, reducing preload and afterload, thereby decreasing myocardial oxygen demand.
FDA-approved: Treatment of moderate to severe pain associated with chronic anal fissures
Prevention of angina pectoris due to coronary artery disease,Off-label: chronic heart failure (as adjunctive therapy), esophageal spasm
1 gram (0.5 mg nitroglycerin) applied intrarectally as an ointment 10-15 minutes before anticipated bowel movement, up to twice daily.
Initial: 30-60 mg orally once daily; titrate to 120 mg once daily as tolerated. Maximum: 240 mg once daily.
Terminal elimination half-life is approximately 2-4 hours in healthy adults. In patients with severe hepatic impairment, half-life may be prolonged up to 8-10 hours, requiring dose adjustment.
Terminal elimination half-life of isosorbide mononitrate is approximately 5 hours. This supports once-daily dosing for IMDUR (extended-release formulation) due to prolonged absorption phase.
Primarily hepatic metabolism via glutathione-organic nitrate reductase, with subsequent denitration and conjugation. Metabolites include inorganic nitrate and 1,2-glyceryl dinitrate. Also undergoes hydrolysis by esterases.
Primarily hepatic metabolism via denitration and glucuronidation; isosorbide mononitrate is the active metabolite of isosorbide dinitrate and does not undergo significant first-pass metabolism.
Primarily renal; approximately 60-70% of the parent drug and metabolites excreted in urine within 24 hours. Fecal elimination accounts for ~20-30% via biliary secretion. Less than 1% unchanged drug recovered in feces.
Isosorbide dinitrate (IMDUR active metabolite? Actually IMDUR is isosorbide mononitrate, the active metabolite of isosorbide dinitrate. For isosorbide mononitrate: renal excretion is approximately 96% as metabolites, with about 2% unchanged; biliary/fecal excretion is minimal, <2%.
Approximately 60% bound to plasma proteins, primarily albumin. Binding is reversible and concentration-dependent.
Less than 5%, primarily to albumin. Very low protein binding, which contributes to high free fraction.
Volume of distribution is approximately 2-4 L/kg, indicating extensive tissue distribution. Clinical meaning: high Vd suggests significant uptake into vascular smooth muscle and other tissues.
Volume of distribution is approximately 0.6-0.7 L/kg for isosorbide mononitrate. This moderate Vd indicates distribution into total body water and some tissue binding.
Sublingual: approximately 40-50% due to first-pass metabolism. Oral: <10% due to extensive hepatic first-pass effect. Topical (RECTIV): systemic bioavailability is negligible (<1%) when applied as directed to the anal mucosa.
Oral bioavailability is nearly 100% for isosorbide mononitrate due to lack of first-pass metabolism (unlike isosorbide dinitrate). For IMDUR extended-release, relative bioavailability is comparable to immediate-release, with controlled release properties.
No dosage adjustment required for renal impairment. Use with caution in severe impairment due to potential for volume depletion.
No dosage adjustment required for GFR ≥30 m L/min. For GFR <30 m L/min, use with caution; consider starting at 30 mg once daily and titrate slowly.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose to 1 gram (0.5 mg) once daily. Child-Pugh C: contraindicated.
Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce dose by 50%; start at 30 mg once daily. Child-Pugh Class C: Contraindicated or use with extreme caution; start at 30 mg once daily with careful monitoring.
Safety and efficacy not established in pediatric patients under 18 years.
Not approved for pediatric use. Limited data: 0.5-2 mg/kg orally once daily, not to exceed 120 mg once daily.
Use with caution; start at lowest effective dose (1 gram) and monitor for hypotension. Consider decreased renal/hepatic function.
Start at 30 mg once daily; titrate slowly due to increased sensitivity and risk of hypotension.
No FDA boxed warning.
Not recommended for use in patients with acute myocardial infarction (MI) or congestive heart failure (CHF) requiring rapid hemodynamic monitoring; use only under close clinical observation.
Hypotension and syncope: Use with caution in patients with hypotension, hypovolemia, or those taking antihypertensives.,Severe anemia or conditions where vasodilation is detrimental.,Concomitant use with phosphodiesterase-5 (PDE-5) inhibitors (e.g., sildenafil) is contraindicated due to risk of severe hypotension.,May cause headaches and local burning or itching at application site.
Hypotension: may cause severe hypotension, especially with upright posture,Tolerance: continuous use may lead to tolerance and cross-tolerance to other nitrates; use with a daily nitrate-free interval,Headache: often occurs but may diminish with continued use,Glaucoma: controversial; generally considered safe,Volume depletion: increased risk of hypotension
Concomitant use of PDE-5 inhibitors (e.g., sildenafil, tadalafil, vardenafil),History of hypersensitivity to nitroglycerin or any component of the formulation,Severe anemia,Increased intracranial pressure (e.g., head trauma, cerebral hemorrhage),Circulatory failure (shock) or severe hypotension
Hypersensitivity to isosorbide mononitrate or other nitrates,Concurrent use with phosphodiesterase-5 inhibitors (e.g., sildenafil, tadalafil, vardenafil) due to risk of severe hypotension,Severe anemia,Increased intracranial pressure (e.g., head trauma, cerebral hemorrhage),Acute circulatory failure or shock
No specific food restrictions. Avoid alcohol as it may worsen hypotension and headache. Grapefruit juice may increase nitroglycerin levels; avoid concurrent consumption.
Avoid high-fat meals as they may delay absorption. No specific food interactions; alcohol may increase hypotensive effects.
Pregnancy Category B. No evidence of teratogenicity in animal studies at doses up to 10 mg/kg/day (approximately 50 times the recommended human dose). No well-controlled studies in pregnant women; use only if clearly needed. Fetal risk cannot be ruled out.
FDA Pregnancy Category C. In animal studies, isosorbide mononitrate (IMDUR) caused embryotoxicity and fetotoxicity at high doses. There are no adequate and well-controlled studies in pregnant women. Use only if potential benefit justifies potential risk to the fetus. First trimester: No specific malformation pattern identified. Second and third trimesters: Potential risk of fetal hypotension and reduced placental perfusion due to maternal vasodilation.
Not recommended during breastfeeding. Drug is administered topically for hemorrhoids; systemic absorption is minimal, but no data on excretion in human milk. M/P ratio not determined.
Unknown if isosorbide mononitrate is excreted in human breast milk. M/P ratio not established. Caution advised; consider discontinuing nursing or drug, balancing importance of drug to mother.
No dose adjustment required; pharmacokinetics not studied in pregnancy. Use the same dose as in non-pregnant patients, but with caution due to lack of safety data.
No specific dose adjustments recommended for pregnancy; however, hemodynamic changes (increased plasma volume, cardiac output) may alter pharmacokinetics. Start at lowest effective dose and titrate based on maternal response and tolerability.
RECTIV (nitroglycerin) 0.4% ointment is indicated for chronic anal fissure pain. Apply a 1-inch strip intra-anally every 12 hours for up to 8 weeks. May cause headache; monitor blood pressure. Contraindicated with PDE5 inhibitors (sildenafil, tadalafil, vardenafil) due to severe hypotension. Avoid in patients with hypotension (SBP <90 mm Hg) or hypovolemia. Do not use with strong CYP3A4 inhibitors (e.g., ritonavir, cobicistat).
Imdur (isosorbide mononitrate) is an extended-release nitrate used for angina prophylaxis. Avoid concomitant use with phosphodiesterase-5 inhibitors (e.g., sildenafil) due to risk of severe hypotension. Tachyphylaxis can occur with continuous use; maintain a daily nitrate-free interval (typically 10-12 hours) to preserve efficacy. Do not crush or chew extended-release tablets. Monitor blood pressure and heart rate during initiation. Use with caution in patients with hypertrophic obstructive cardiomyopathy, aortic stenosis, or volume depletion.
Apply 1-inch strip of ointment inside the anus every 12 hours using the applicator.,Wash hands before and after application.,Do not use more than 8 weeks unless directed by your doctor.,Avoid sexual activity during treatment as partner may absorb medication.,Do not take erectile dysfunction drugs (Viagra, Cialis, Levitra) while using this medication.,Seek medical help if you experience severe headache, dizziness, or fainting.,Store at room temperature away from heat and direct light.,Do not use if you have low blood pressure or are dehydrated.
Take Imdur exactly as prescribed, usually once daily in the morning to maintain a nitrate-free interval.,Do not crush, chew, or cut the tablet; swallow it whole with a glass of water.,Avoid taking erectile dysfunction medications (e.g., Viagra, Cialis, Levitra) while on Imdur, as this can cause a dangerous drop in blood pressure.,If you experience headache, it may indicate the drug is working; acetaminophen can help. Inform your doctor if headaches persist.,Store at room temperature, away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about RECTIV vs IMDUR, answered by our medical review team.
RECTIV is a Nitrate Vasodilator that works by RECTIV (nitroglycerin) is a nitric oxide (NO) donor that relaxes vascular smooth muscle via stimulation of intracellular cyclic guanosine monophosphate (c GMP) production, leading to vasodilation. In chronic anal fissures, it reduces internal anal sphincter pressure and improves blood flow to the anoderm.. IMDUR is a Nitrate Vasodilator that works by Isosorbide mononitrate is a nitrate vasodilator that relaxes vascular smooth muscle via conversion to nitric oxide (NO), which activates guanylate cyclase, increasing c GMP levels, leading to vasodilation. It primarily dilates veins (venodilation) with lesser effects on arteries, reducing preload and afterload, thereby decreasing myocardial oxygen demand.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between RECTIV and IMDUR depend on the specific clinical indication. These are both Nitrate Vasodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of RECTIV is: 1 gram (0.5 mg nitroglycerin) applied intrarectally as an ointment 10-15 minutes before anticipated bowel movement, up to twice daily.. The standard adult dose of IMDUR is: Initial: 30-60 mg orally once daily; titrate to 120 mg once daily as tolerated. Maximum: 240 mg once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between RECTIV and IMDUR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. RECTIV is classified as Category C. Pregnancy Category B. No evidence of teratogenicity in animal studies at doses up to 10 mg/kg/day (approximately 50 times the recommended human dose). No well-controlled studies in. IMDUR is classified as Category C. FDA Pregnancy Category C. In animal studies, isosorbide mononitrate (IMDUR) caused embryotoxicity and fetotoxicity at high doses. There are no adequate and well-controlled studies . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.